0G8X Stock Chart & Stats
kr0.17
>-kr0.01(-5.27%)
At close: 4:00 PM EDT
kr0.17
>-kr0.01(-5.27%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.72
Previous CloseN/A
Volume17.50K
Average Volume (3M)19.36K
Market Cap
kr101.30M
Enterprise Valuekr99.54
Total Cash (Recent Filing)kr34.90M
Total Debt (Recent Filing)kr3.27M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume1,391
30 Day Avg. Volume19,363
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)kr3.00M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationStrong sensitivity and specificity support the test’s clinical credibility and may improve its prospects for physician adoption, payer review and regulatory progress. This evidence can underpin broader commercialization if ongoing utility studies confirm real-world value.
Commercial TractionExpansion across high-risk programs and leading cancer centers indicates growing market access and customer interest. A larger engaged pipeline creates a foundation for recurring test volumes, although conversion into repeat orders remains important.
Low Financial LeverageLimited financial debt reduces interest and refinancing pressure compared with a highly leveraged diagnostics company. This provides some balance-sheet flexibility while Immunovia pursues commercialization, partnerships and funding to support continued operations.
Bears Say
Unprofitable Operating ModelRevenue remains far below the cost base, producing deeply negative gross profit and substantial net losses. Unless test volumes scale materially or expenses decline, the company’s path to breakeven remains uncertain and equity value may continue to erode.
Cash Runway And Funding RiskA limited runway makes external financing or a strategic partnership important to sustaining operations and funding clinical and commercial expansion. Financing needs could constrain strategy, increase dilution risk or disrupt execution if capital is delayed.
Reimbursement UncertaintyUncertain reimbursement levels and timing make it difficult to forecast realized pricing, customer economics and demand. Restricted initial coverage among symptomatic high-risk patients could also limit the addressable market and slow adoption.
Immunovia AB News
0G8X FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest share price was kr0.15 and its highest was kr0.72 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr101.30M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -kr0.03 earnings per share for the quarter, beating the consensus estimate of -kr0.04 by kr0.01.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.02.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, beating expectations of -kr0.04. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in GB:0G8X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
0G8X Company Deck
0G8X Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of meaningful commercial and clinical progress alongside material operational and financing risks. Key positives include very strong percentage revenue growth, robust clinical performance (83.3% sensitivity, ~92% specificity), major center uptake, and an expanding engaged pipeline. Offsetting these are still-modest absolute revenues, an increased operating loss due to higher personnel and study spending, limited cash runway into Q4 2026 requiring near-term financing or partnerships, and uncertainty around reimbursement levels and timing. Overall, the company is showing clear early commercial and clinical traction but remains exposed to execution and funding risks as it scales.View all GB:0G8X earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―